AZA has previously been shown to up-regulate tumor antigen expression on AML blasts and can also induce a CD8+ T-cell response post-allograft (19, 31), whereas post-allograft lenalidomide induces strong NK cell-mediated anti-tumor activity (23). The gene discussed is CD8A; the disease is acute myeloid leukemia.